Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of age on the risk of immune-related adverse events in patients receiving immune checkpoint inhibitors
Kaili Yang, Jiarui Li, Zhao Sun, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 7, pp. 3907-3918
Closed Access | Times Cited: 11

Showing 11 citing articles:

Management of immune checkpoint inhibitor-associated toxicities in older adults with cancer: recommendations from the International Society of Geriatric Oncology (SIOG)
Colm Mac Eochagáin, Nina Rosa Neuendorff, Karolina Gente, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 2, pp. e90-e102
Closed Access | Times Cited: 2
Detection Algorithms for Simple Two-Group Comparisons Using Spontaneous Reporting Systems
Yoshihiro Noguchi, Tomoaki Yoshimura
Drug Safety (2024) Vol. 47, Iss. 6, pp. 535-543
Closed Access | Times Cited: 15
Anti-PD-1 exacerbates bleomycin-induced lung injury in mice via Caspase-3/GSDME-mediated pyroptosis
Fei Wang, Haiyi Deng, Maolin Zhou, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access
Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors
Xiao Hu, Angie Mae Rodday, Anastasia Gurinovich, et al.
Immunotherapy (2025), pp. 1-9
Closed Access
The Clinical Analysis of Checkpoint Inhibitor Pneumonitis with Different Severities in Lung Cancer Patients: A Retrospective Study
Hui Huang, Ruxuan Chen, Yan Xu, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 1, pp. 255-255
Open Access | Times Cited: 2
Toxicity of Cancer Immunotherapies in Older Patients: Does Age Make a Difference?
Emine Çil, Fábio Gomes
Drugs & Aging (2024) Vol. 41, Iss. 10, pp. 787-794
Closed Access | Times Cited: 2
Tumor Lysis Syndrome with CD20 Monoclonal Antibodies for Chronic Lymphocytic Leukemia: Signals from the FDA Adverse Event Reporting System
Shuang Xia, Jiating Ma, Emanuel Raschi, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 10, pp. 773-783
Closed Access | Times Cited: 5
Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma
Fabian Ullrich, Paul J. Bröckelmann, Amin T. Turki, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 12, pp. e009462-e009462
Open Access | Times Cited: 1
Disproportional signal of pericarditis with biological diseasemodifying antirheumatic drugs (bDMARDs) in patients with ankylosing spondylitis: a disproportionality analysis in the FAERS database
Shuang Xia, Yunfei Li, Emanuel Raschi, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system
Ling Liu, Chengyi Zhang, Huihui Liu, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 9, pp. 1199-1205
Closed Access
[Advances in Predictive Research of Immune Checkpoint Inhibitors-related 
Adverse Events].
Jing Zhang, Xueqin Chen, Shenglin Ma
PubMed (2023) Vol. 26, Iss. 10, pp. 789-794
Closed Access
Page 1

Scroll to top